

# The Opioid Crisis: Maryland Healthcare Reacts

**Wednesday,  
November 9, 2016**

Turf Valley  
2700 Turf Valley Road  
Ellicott City, MD 21042



## Who Should Attend?

Pharmacists, physicians, medication safety officers, nurses, quality managers, risk managers, and patient safety officers

## Program Fee

- Program fee: \$199
- On-site fee: \$250
- FREE for individuals from MPSC member organizations (must register by October 28, 2016\*)

\* Per MPSC's cancellation policy effective July 1, 2015, cancellation from member organizations after October 31, 2016 and "no shows" the day of the event will be assessed a fee of \$75.

This activity is jointly provided by  
AXIS Medical Education  
and Maryland Patient  
Safety Center.

## PROGRAM AGENDA

**8:00 am** Registration and Continental Breakfast  
**8:30 am** Welcome and Introductions  
Robert H. Imhoff, III  
President & CEO  
Maryland Patient Safety Center  
**8:45 am** Keynote: Opioid as Pharmakon: Harm and Healing from the 19th Century to the Present Day  
Mishka Terplan, MD, MPH, FACOG, Diplomate ABAM

## Educational Objectives

*After completing this activity, the participant should be better able to:*

1. Review the history of opioid use in the United States with particular attention to the current opioid epidemics
2. Review the regulatory environment for use of opioids, treatment of opioid use disorders, and how this impacts patient management
3. Counsel patients and families on the risks and signs of dependency when providing prescription opioids for pain management.
4. Review the tools available to help combat the opioid overdose epidemic

## Faculty



### Keynote Speaker:

**Mishka Terplan, MD, MPH, FACOG, Diplomate ABAM; Medical Director Behavioral Health System Baltimore**

Dr. Mishka Terplan is board certified in both addiction medicine and obstetrics and gynecology. He attended medical school at the University of California San Francisco, residency at the University of Southern California, and completed a fellowship in clinical research at the University of North Carolina, Chapel Hill. He currently is Medical Director of Behavioral Health System Baltimore where he oversees multiple public health projects related to substance use including the Baltimore Buprenorphine Initiative.



### Closing Keynote:

**Dennis M. Dimitri, MD: Immediate Past President, Massachusetts Medical Society**

Dennis M. Dimitri MD, FAAFP is a Clinical Associate Professor and Vice Chair of the Department of Family Medicine

5. Outline the legislative changes to the PDMP impacting clinicians in the next two years
6. Discuss what policy, legislation, or alternative programs have been initiated as a result of the Maryland Heroin and Opioid Emergency Task Force recommendations, and their impact
7. Outline how a health care organization, reaching out to its prime constituencies of physicians and patients, can become a leader in addressing a major public health issue negatively affecting both of those constituencies.

& Community Health at University of Massachusetts Memorial Medical Center and University of Massachusetts Medical School. He is the immediate past president of the Massachusetts Medical Society, serving in that office for 2015-2016. In that role, he was instrumental in developing pain management guidelines for physicians to assist them in managing patient's pain, and initiating conversation with patients about risks, benefits and possible alternatives to opioids as health care talks to patients about the opioid overdose crisis. He encourages physicians to prescribe smaller doses of opioids.

### Featured Speakers:

**Yngvild K. Olsen, MD, MPH: Medical Director of the Institutes for Behavior Resources Inc./REACH Health Services, Baltimore City**

**Ginger Rosela: Patient and Family Advocate**

**Kelly E. Dunn, MS, PhD: Assistant Professor of Psychiatry and Behavioral Sciences, Johns Hopkins Medicine**

**Kate Jackson, MPH: PDMP Manager, Maryland Behavioral Health Administration**

**Sheriff Timothy Cameron, St. Mary's County, Maryland, Member, Maryland's Heroin and Opioid Emergency Task Force**

Medical Director  
Behavioral Health System Baltimore

**9:45 am** Break

**10:00 am** Opioids and Opioid Addiction: Practical Management Approaches

Yngvild K. Olsen, MD, MPH

Medical Director of the Institutes for Behavior Resources Inc./REACH Health Services, Baltimore City

**11:00 am** Jake's Story

Ginger Rosela

Patient and Family Advocate

**12:00 pm** Lunch (provided)

**12:45 pm** Combating Opioid-related Overdose

Kelly E. Dunn, MS, PhD

Assistant Professor of Psychiatry and Behavioral Sciences  
Johns Hopkins Medicine

**1:45 pm** Maryland Prescription Drug Monitoring Program (PDMP)

Kate Jackson, MPH

PDMP Manager, Maryland Behavioral Health Administration

**2:00 pm** The Governor's

Heroin and Opioid Emergency

Task Force Final Report Recommendations

Sheriff Timothy Cameron

St. Mary's County, Maryland Member, Maryland's Heroin and Opioid Emergency Task Force

**2:30 pm** Closing Keynote:

Physicians Respond to the Opioid Epidemic: The Massachusetts Experience

Dennis M. Dimitri, MD

Immediate Past President

Massachusetts Medical Society

**3:30 pm** Adjournment

# CONTINUING EDUCATION

## Accreditation Statement

This activity is planned and implemented by AXIS Medical Education and *Maryland Healthcare Education Institute*. AXIS Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

## Credit Designation for Physicians

AXIS Medical Education designates this

live activity for a maximum of 5.75 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Credit Designation for Pharmacists

This knowledge-based activity is approved for 5.75 contact hours of continuing pharmacy education credit (UAN 0592-9999-16-021-L01-P).

## Credit Designation for Nursing

AXIS Medical Education designates this

continuing nursing education activity for 5.75 contact hours.

*Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.*

## AXIS Contact Information

For information about the accreditation of this program please contact AXIS at 954-281-7524 or [info@axismeded.org](mailto:info@axismeded.org).

## DISCLOSURE OF CONFLICTS OF INTEREST

The **Faculty** reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter	Reported Financial Relationship
Mishka Terplan, MD, MPH, FACOG, Diplomate ABAM	Nothing to disclose
Yngvild K. Olsen, MD, MPH	Receives income from <i>Audacious Inquiry</i> , a health information technology and policy company.
Ginger Rosela	Nothing to disclose
Kelly, E. Dunn, MS, PHD	Research Grants: Principal Investigator on investigator-initiated National Institute on Drug Abuse (NIDA) grants Contracted Research: Ashley Addiction Treatment contract for outcomes research.
Kate Jackson, MPH	Nothing to disclose
Timothy Cameron	Nothing to disclose
Dennis M. Dimitri, MD	Nothing to disclose

The **planners and managers** reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Planner/Manager	Reported Financial Relationship
Bonnie DiPietro, MS, RN, NEA-BC, FACHE	Nothing to disclose
Alison Burrows	Nothing to disclose
Kelly Heacock	Nothing to disclose
Holly M. Hampe, D.Sc., RN, MHA, MRM	Nothing to disclose
Dee Morgillo, MEd., CHCP	Nothing to disclose

## DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

## DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of

published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

## AMERICANS WITH DISABILITIES ACT

In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request. For any special requests, please contact Maryland

Healthcare Education Institute at 410-796-6239 before the meeting dates.

## Requirements for credit:

- Attend/participate in the educational activity and review all course materials.
- Complete the CE Declaration form online by 11:59 pm ET November 23, 2016. Instructions will be provided. If you do not enter the online portal by the above date, you will not be able to retrieve your statement of participation.
- Upon successful completion of the online form, your statement of completion will be presented to you to print. For pharmacists, your record will be automatically uploaded to CPEDMonitor.